NHI | Ticker Profile - Titan Protect

NHI

National Health Investors, Inc.

Real Estate · REIT - Healthcare Facilities · NYQ

$70.43

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.6B

Total market value of the company

Trailing P/E

24.17

Premium valuation

Forward P/E

20.68

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.6%

Year-over-year revenue change

Profit Margin

36.6%

How much profit the company keeps from each dollar of revenue

ROE

9.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$88.50

+26% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 8 analysts covering this stock

About National Health Investors, Inc.

National Health Investors, Inc. is a self-managed real estate investment trust specializing in sale-leaseback, joint venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical facility investments. NHI's portfolio consists of independent living facilities, assisted living and memory care communities, entrance-fee retirement communities, senior living campuses, skilled nursing facilities and specialty hospitals. National Health Investors, Inc. was established on October 15th 1991 and was incorporated in 1991 in Maryland and is based in Murfreesboro, United States.

https://www.nhireit.com

Country: United States Employees: 32 Industry: REIT - Healthcare Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.726

Good returns relative to risk taken

Kelly Fraction

0.0572

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.668

Acceptable balance between returns and drawdown risk

Annual Return

13.9%

Historical annualised return based on price data

Max Drawdown

-20.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

497

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.58

Less volatile than the market — more defensive

52W High

$91.38

23% below the year high

52W Low

$68.80

2% above the year low

Avg Volume

375,540

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.0%

Low short interest — limited bearish positioning

Div Yield

491.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$3.10

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

97.57

Heavy leverage — higher financial risk if revenues decline

Current Ratio

0.60

Below 1 means short-term obligations exceed liquid assets — risk flag

Quick Ratio

0.55

Like current ratio but excludes inventory — stricter test

Gross Margin

78.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

61.3%

Profit from core operations before interest and tax

Free Cash Flow

$208M

Positive — the business generates more cash than it spends

Revenue (TTM)

$405M

Total revenue over the last 12 months

Net Income

$148M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$91.00

Target Median

$88.50

Target Low

$74.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go